COMPARATIVE ANALYSIS OF PHARMACOKINETIC (PK) STUDY DATA BETWEEN EXTENDED HALF-LIFE (EHL) AND STANDARD HALF-LIFE (SHL) FACTOR PRODUCTS: EXPERIENCE FROM GREEK ADULT HAEMOPHILIA CENTRE

被引：0
|
作者：
Christoforou, P. [1 ,2 ]
Kourampa, A. [1 ,2 ]
Varaklioti, A. [1 ,2 ]
Pirpiri, T. [1 ,2 ]
Balomenou, A. [1 ,2 ]
Katsarou, O. [1 ,2 ]
机构：
[1] Laikon Gen Hosp, Blood Unit, Athens, Greece
[2] Laikon Gen Hosp, Natl Reference Ctr Congenital Bleeding Disorders, Athens, Greece
来源：
HAEMOPHILIA | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO074
引用
收藏
页码：61 / 61
页数：1
相关论文
共 50 条
  • [1] Single centre experience of switching from standard half-life to extended half-life products in patients with severe haemophilia A and B
    Phillott, Anica
    Stanley, Jenna
    Alamelu, Jayanthi
    HAEMOPHILIA, 2018, 24 : 32 - 33
  • [2] PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS
    Megias Vericat, J. E.
    Bonanad-Boix, S.
    Martinez Garcia, M. F.
    Berrueco, R.
    Mingot-Castellano, M. E.
    Rodriguez, M.
    Canaro, M.
    Mateu, J.
    Larrode, I.
    Haya, S.
    Santamaria, A.
    Mesegue, M.
    Albo, C.
    Palomero, A.
    Vilalta, N.
    Calvo, J. M.
    Cid, A. R.
    Poveda, J. L.
    Iorio, A.
    HAEMOPHILIA, 2020, 26 : 88 - 89
  • [3] PK-guided switch from standard half-life to extended half-life factor VIII products
    Eduardo Megias-Vericat, Juan
    Bonanad, Santiago
    Martinez Garcia, Maria Fernanda
    Berrueco Moreno, Ruben
    Maria Mingot-Castellano, Eva
    Rodriguez Lopez, Manuel
    Canaro Hirnyk, Mariana
    Mateo Arranz, Jose
    Calvo Villas, Jose Manuel
    Haya, Saturnino
    Rosa Cid, Ana
    Iorio, Alfonso
    HAEMOPHILIA, 2020, 26 : 17 - 18
  • [4] Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products
    Megias-Vericat, J. E.
    Bonanad Boix, S.
    Berrueco Moreno, R.
    Mingot-Castellano, M. E.
    Rodriguez Lopez, M.
    Canaro Hirnyk, M.
    Mateo Arranz, J.
    Calvo Villas, J. M.
    Haya Guaita, S.
    Mesegue Meda, M.
    Lopez Jaime, F.
    Albo-Lopez, C.
    Palomero-Massanet, A.
    Vilalta Seto, N.
    Larrode Lecinena, I
    Cid Haro, A. R.
    Poveda Andres, J. L.
    THROMBOSIS RESEARCH, 2022, 216 : 35 - 42
  • [5] ENHANCED HALF-LIFE (EHL) VS. STANDARD HALF-LIFE (SHL) REPLACEMENT FACTORS IN HAEMOPHILIA A AND B: APPLICATION OF A HAEMOPHILIA VALUE FRAMEWORK
    Skinner, M.
    Dolan, G.
    Eichler, H.
    O'Mahony, B.
    HAEMOPHILIA, 2021, 27 : 71 - 72
  • [6] Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products
    Eduardo Megias, Juan
    Bonanad Boix, Santiago
    Martinez Garcia, Maria Fernanda
    Berrueco, Ruben
    Eva Mingot-Castellano, Maria
    Rodriguez Lopez, Manuel
    Canaro, Mariana
    Mateo Arranz, Jose
    Larrode Lecinena, Itziar
    Haya, Saturnino
    Santamaria Ortiz, Amparo
    Albo, Carmen
    Mesegue Medea, Montserrat
    Palomero-Massanet, Antonio
    Vilalta Seto, Noelia
    Calvo Villas, Jose Manuel
    Cid, Ana R.
    Robayo, Gustavo
    Poveda Andres, Jose Luis
    Sanz, Guillermo F.
    Iorio, Alfonso
    BLOOD, 2019, 134
  • [7] PHARMACOKINETIC DRUG EVALUATION OF STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII IN PATIENTS WITH HEMOPHILIA A
    Lopez-Jaime, F-J
    Perez-Raya, M.
    Doblas-Marquez, A.
    Martin-Tellez, S.
    Mena-Santano, A-M
    Munoz-Lopez, F-D
    HAEMOPHILIA, 2021, 27 : 107 - 107
  • [8] Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B
    Chhabra, Amit
    Spurden, Dean
    Fogarty, Patrick F.
    Tortella, Bartholomew J.
    Rubinstein, Emily
    Harris, Simon
    Pleil, Andreas M.
    Mellor, Jennifer
    de Courcy, Jonathan
    Alvir, Jose
    BLOOD COAGULATION & FIBRINOLYSIS, 2020, 31 (03) : 186 - 192
  • [9] PHARMACOKINETIC AND COST CONSIDERATIONS FOR TRANSITION TO EXTENDED HALF-LIFE (EHL) FACTOR VIII AND IX PRODUCTS
    Croteau, Stacy
    Neufeld, Ellis
    PEDIATRIC BLOOD & CANCER, 2015, 62 : 46 - 46
  • [10] Pharmacokinetic and Cost Considerations for Transition to Extended Half-life (EHL) Factor VIII and IX Products
    Croteau, S.
    Neufeld, E.
    HAEMOPHILIA, 2015, 21 (03) : E262 - E262
12345